Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · IEX Real-Time Price · USD
22.61
+0.08 (0.36%)
Apr 18, 2024, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for ARWR stock have an average target of 55.08, with a low estimate of 34 and a high estimate of 90. The average target predicts an increase of 143.61% from the current stock price of 22.61.
Analyst Consensus: Buy
* Price targets were last updated on Feb 8, 2024.
Analyst Ratings
The average analyst rating for ARWR stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 15 | 14 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +298.05% | Feb 8, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $34 → $36 | Hold | Maintains | $34 → $36 | +59.22% | Feb 7, 2024 |
| Citigroup | Citigroup | Hold Maintains $33 → $34 | Hold | Maintains | $33 → $34 | +50.38% | Feb 7, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $50 | Buy | Reiterates | $50 | +121.14% | Feb 7, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $50 | Buy | Reiterates | $50 | +121.14% | Jan 16, 2024 |
Financial Forecast
Revenue This Year
141.81M
from 240.74M
Decreased by -41.09%
Revenue Next Year
161.09M
from 141.81M
Increased by 13.60%
EPS This Year
-2.72
from -1.92
EPS Next Year
-2.69
from -2.72
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 317.1M | 300.4M | 530.3M | 937.7M | 1.5B |
| Avg | 141.8M | 161.1M | 290.5M | 563.1M | 970.1M |
| Low | 52.5M | n/a | 190.6M | 142.1M | 198.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.7% | 111.8% | 229.2% | 222.7% | 167.5% |
| Avg | -41.1% | 13.6% | 80.3% | 93.8% | 72.3% |
| Low | -78.2% | - | 18.3% | -51.1% | -64.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.32 | -1.53 | -1.23 | 6.31 | 7.72 |
| Avg | -2.72 | -2.69 | -2.39 | 1.54 | 3.60 |
| Low | -3.99 | -3.90 | -3.25 | -1.27 | 0.98 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 401.9% |
| Avg | - | - | - | - | 134.3% |
| Low | - | - | - | - | -36.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.